Reference
Yokoyama A, et al. Pulmonary adenocarcinoma, harboring both an EGFR mutation and ALK rearrangement, presenting a stable disease to erlotinib and a partial response to alectinib. Internal Medicine 57: 2377-2382, No. 16, Jan 2018. Available from: URL: http://doi.org/10.2169/internalmedicine.0383-17 - Japan
Rights and permissions
About this article
Cite this article
Alectinib. Reactions Weekly 1718, 20 (2018). https://doi.org/10.1007/s40278-018-51364-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-51364-x